Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biomarker Predicts Chemo Response for Osteosarcoma

Published: Wednesday, July 04, 2012
Last Updated: Wednesday, July 04, 2012
Bookmark and Share
Scientists have found that a protein expressed by some cancers is a good predictor of how the cancer will respond to standard chemotherapy.

Knowing whether a patient's tumor has this protein biomarker could help doctors determine if a patient should undergo standard treatment or if a more aggressive or alternative therapy may be more effective.

"This is the first time that a biomarker has been identified that predicts treatment success for osteosarcoma," said Dariusz Borys, assistant professor in the UC Davis Department of Pathology and Laboratory Medicine and lead author of the study. "It is a first step in individualizing therapy to maximize success based on a protein that the cancer expresses."

Osteosarcoma is usually diagnosed during the teenage years. It also may affect people over 60.

Osteosarcoma is typically treated with "neoadjuvant therapy," which involves several cycles of chemotherapy using a combination of drugs to shrink the tumor before it is surgically removed. How effective the chemotherapy is in inducing cancer cell death (necrosis) is the best predictor of a patient's survival following surgery. But a tumor's response to chemotherapy varies widely among patients and, until now, a way to predict whether the chemotherapy will work well has not been identified.

The investigators focused on a protein expressed by cancer cells known as P16, which inhibits cell growth. For unknown reasons, some cancers stop expressing P16. The researchers found that patients who had cancers that still expressed P16 were more likely to respond well to chemotherapy.
"It is useful to know ahead of time if patients are likely to respond to standard therapy," said Borys. "Those who have tumors that do not express P16 would be especially good candidates for more aggressive or experimental treatments to see if they might respond better."

The study enrolled 40 patients, aged 9 to 75 years old (median age, 15 years), with osteosarcoma at UC Davis and UC San Francisco. Pathologic specimens of the tumors before treatment were collected for study from each patient and were analyzed for P16 expression. After chemotherapy, during surgery to remove the tumor, specimens were again collected and analyzed for the extent of tumor cell death. A little more than half of the patients responded well to chemotherapy, and these patients were found to be significantly more likely to have had tumors that expressed the P16 protein.

Data on how the patients fared clinically were not available for this study, but it has been well established from other studies that the amount of tumor killed preoperatively is strongly associated with survival.

Borys said more patients will be studied to strengthen the findings, and on a molecular level, more study is needed to clarify why some cancer cells stop expressing P16.

The study was a collaboration among three institutions on the West Coast (UC Davis, UC San Francisco and University of Washington) and involved pathologists and surgeons. According to Borys, pathologists traditionally have been used to help establish a diagnosis, but are now moving toward an equally important role in helping clinicians determine treatment strategies.

"Pathologists will one day be able to provide answers to better help clinicians cure their patients," said Borys. "Our work to improve the treatment of osteosarcoma is an important step in that direction."
The article is titled, "P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy."

Other UC Davis study authors were Robert J. Canter and Steve R. Martinez, surgical oncologists at the Comprehensive Cancer Center, Robert M. Tamurian of the Department of Orthopedic Surgery, John Bishop of the Department of Pathology and Laboratory Medicine and Brian Murphy of the Veterinary School's Department of Pathology. Andrew Horvai of the UC San Francisco Medical Center was co-principal investigator with Borys. Benjamin Hoch of the University of Washington was another study author.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

RNA-Binding Proteins Role in ALS Revealed
Researchers describe how damage to RNA-binding protein contributes to ALS, isolating a possible therapeutic target.
Monday, October 24, 2016
Transcription Factor Isoforms Implicated in Colon Diseases
UC Riverside study explains how distribution of two forms of a transcription factor in the colon influence risk of disease.
Thursday, May 19, 2016
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Monday, February 08, 2016
Embryonic Switch for Cancer Stem Cell Generation
An international team of scientists report that decreases in a specific group of proteins trigger changes in the cancer microenvironment that accelerate growth and development of therapy-resistant cancer stem cells (CSCs).
Wednesday, December 02, 2015
Artificial Kidney Research Gets A Boost
Development of a surgically implantable, artificial kidney — a promising alternative to kidney transplantation or dialysis for people with end-stage kidney disease — has received a $6 million boost.
Monday, November 09, 2015
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Tuesday, July 28, 2015
Growing Spinal Disc Tissue
Scientists develop new method for growing spinal disc tissue in the lab for combating chronic back pain.
Friday, July 03, 2015
Grant Supports Creation of Patient-Derived Stem Cell Lines
Researchers have received a two-year, $600,000 grant from the National Institute on Aging to develop and study patient-derived stem cell lines.
Thursday, December 12, 2013
Prostate Cancer Stem Cells are a Moving Target
Researchers have discovered how prostate cancer stem cells evolve as the disease progresses, a finding that could help point the way to more highly targeted therapies.
Friday, December 06, 2013
Researchers Change Cell Types by Flipping a Single Switch
New findings have identified a method for changing one cell type into another in a process called forced transdifferentiation.
Friday, December 06, 2013
Understanding a Protein’s Role in Familial Alzheimer’s
Researchers have used genetic engineering of human iPSC’s to specifically and precisely parse the roles of a key mutated protein in causing familial Alzheimer's disease (AD).
Monday, November 18, 2013
Researchers Un-Junking Junk DNA
A study shines a new light on molecular tools our cells use to govern regulated gene expression.
Wednesday, November 13, 2013
$100M gift launches Sanford Stem Cell Clinical Center
T. Denny Sanford has committed $100 million to the creation of the Sanford Stem Cell Clinical Center at the University of California, San Diego.
Wednesday, November 06, 2013
Grafted Limb Cells Acquire Molecular ‘Fingerprint’ of New Location
Findings further creation of regenerative therapies for humans.
Wednesday, October 30, 2013
From Mature Cells to Embryonic-Like Stem Cells
Bioengineers have shown that physical cues can replace certain chemicals when nudging mature cells back to a pluripotent stage.
Tuesday, October 22, 2013
Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Defining Immortality of Stem Cells
Researchers defined the mechanisms underlying increased protein quality control of pluripotent stem cells.
Enhancing CRISPR to Explore Further
Researchers have developed sOPTiKO, a more efficient and controllable CRISPR genome editing platform.
Regenerating Diseased Hearts
Researchers from the University of Otago have probed the potential of adult stem cell types to repair diseased hearts.
Stem Cells Police Themselves to Reduce Scarring
Scientists have discovered stem cells in muscle fibers change gene expressions to respond to injury.
Bright Red Fluorescent Protein Created
Scientists have created a bright red, fluorescent protein that could be used to track essential cellular processes.
Protein Self-Regulates Abundance
Researchers have uncovered how a protein, that plays a crucial role in embryonic stem cell renewal, is regulated.
Topical Immunotherapy Effective Against Early Skin Cancer
Combination of two commonly used drugs triggers immune response against precancerous skin lesions.
Factors Behind Suppression of Stem Cell Mobilization Revealed
The findings could lead to improvements in transplantation therapy.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!